Neutral
T. Rowe Price holds 5.4% of Denali Therapeutics (NASDAQ: DNLI)
T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, disclosing a 5.4% beneficial ownership stake in Denali Therapeutics (NASDAQ: DNLI)...